UCB SA (OTCMKTS:UCBJY) Stock Short Interest Jumps 183.2%

UCB SA (OTCMKTS:UCBJY) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 42,361 shares, an increase of 183.2% from the August 31st total of 14,956 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 100,514 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

UCBJY has been the topic of a number of research analyst reports. Zacks Research downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 16th. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

UCB Trading Up 1.6%

OTCMKTS:UCBJY opened at $122.64 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average price of $127.24 and a 200 day moving average price of $139.00. UCB has a fifty-two week low of $115.19 and a fifty-two week high of $168.76.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.